Video

Dr. Untch on the Expanding Use of Biosimilars

Michael Untch, MD, PhD, discusses the widespread use of biosimilars in Europe.

Michael Untch, MD, PhD, professor, chief physician, Obstetrics and Gynecology, Helios Hospital Berlin-Buch, Berlin, Germany, discusses the widespread use of biosimilars in Europe.

Following the introduction of ABP 980 (Kanjinti; trastuzumab-anns), a biosimilar for trastuzumab (Herceptin) over 1 year ago, biosimilars have gained traction in Germany, explains Untch. Now, several additional biosimilars for trastuzumab have been approved in Europe.

Biosimilars are used widely in Europe, says Untch. He suggests that the money saved from using biosimilars could be redirected to further research and therapeutic development for patients.

Although there is still some resistance toward biosimilars in the United States, Untch is certain their adoption in Europe will continue to expand as more biosimilars are introduced.

Related Videos
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.
Neal D. Shore, MD, FACS
Sheldon M. Feldman, MD
Louis Crain Garrot, MD
Michel Delforge, MD, PhD
Thach-Giao Truong, MD
Aparna Parikh, MD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec